Apogee Therapeutics CEO Michael Thomas Henderson gifted 75,046 shares to a donor-advised fund and sold 20,000 shares under a Rule 10b5-1 trading plan adopted in August 2025, according to an SEC filing. The sale was executed at a weighted average price of $133.63, while the stock closed at $133.65 on July 10, 2026, giving his remaining 920,941 directly held shares a value of approximately $123.08 million. The company, which has a market capitalization of $8.2 billion and a one-year stock return of 247%, reported a net loss of $274.6 million over the trailing twelve months. Apogee’s lead candidate zumilokibart recently posted positive 52-week Phase 2 data in atopic dermatitis, with a Phase 3 trial expected to start in the second half of 2026, and a $403 million equity raise has extended its cash runway into 2029.
Apogee Therapeutics, Inc. Common StockCEO gifted and sold shares under a pre-set plan, but the stock's fundamentals (positive Phase 2 data, cash runway) are unchanged.